Skip to main content
Top
Published in: Current Geriatrics Reports 4/2014

01-12-2014 | Cardiovascular Disease in the Elderly (DE Forman, Section Editor)

What Should the Systolic Blood Pressure Treatment Goal Be in Patients Aged 60 Years and Older with Hypertension?

Author: Wilbert S. Aronow

Published in: Current Geriatrics Reports | Issue 4/2014

Login to get access

Abstract

While there is consensus that high blood pressure in older adults should be treated, there is significant variability among prominent therapeutic guidelines. This review will present seminal anti-hypertension trials establishing efficacy of BP-lowering therapy. Subanalyses focused on efficacy of antihypertensive therapy as part of management strategies for diverse CV diseases will also be provided. On the basis of these analyses, recommended guidelines will then be assessed. Guidelines from the recently published Eighth Joint National Committee (JNC 8) will be compared to the 2011 American College of Cardiology Foundation/American Heart Association, 2013 American Diabetes Society, 2012 International Society of Nephrology, and 2013 European Society of Hypertension/European Society of Cardiology guidelines for management of hypertension. Whereas most guidelines recommend treating systolic blood pressure in older adults to <140 mmHg, the JNC 8 recommendations are notably higher, targeting SBP of <150 mmHg for patients who do not have diabetes or CKD. To many experts, including this author, the higher target threshold seems imprudent, as increased risk for CV events likely outweighs any benefits.
Literature
1.
go back to reference Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–181.PubMedCrossRef Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21–181.PubMedCrossRef
2.
go back to reference Aronow WS, Ahmed MI, Ekundayo OJ, Allman RM, Ahmed A. A propensity-matched study of the association of PAD with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol. 2009;103:130–5.PubMedCentralPubMedCrossRef Aronow WS, Ahmed MI, Ekundayo OJ, Allman RM, Ahmed A. A propensity-matched study of the association of PAD with cardiovascular outcomes in community-dwelling older adults. Am J Cardiol. 2009;103:130–5.PubMedCentralPubMedCrossRef
3.••
go back to reference Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–114. This expert consensus document on hypertension in the elderly recommends that systolic blood pressure be lowered to <140 mmHg in older persons < 80 years of age and to 140–145 mmHg, if tolerated, in adults aged 80 years and older.PubMedCrossRef Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–114. This expert consensus document on hypertension in the elderly recommends that systolic blood pressure be lowered to <140 mmHg in older persons < 80 years of age and to 140–145 mmHg, if tolerated, in adults aged 80 years and older.PubMedCrossRef
4.••
go back to reference Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219. These guidelines recommend lowering the systolic blood pressure to < 140 mmHg in patients at low to moderate cardiovascular risk, diabetics, patients with prior stroke or transient ischemic attack, and patients with coronary heart disease or chronic kidney disease. In older patients < 80 years of age with systolic blood pressure ≥ 160 mmHg, the systolic blood pressure should be lowered to 140–150 mmHg, with consideration of <140 mmHg. In patients >80 years of age with systolic blood pressure ≥ 160 mmHg, the systolic blood pressure should be lowered to 140–150 mmHg, provided they are in good physical and mental condition.PubMedCrossRef Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159–219. These guidelines recommend lowering the systolic blood pressure to < 140 mmHg in patients at low to moderate cardiovascular risk, diabetics, patients with prior stroke or transient ischemic attack, and patients with coronary heart disease or chronic kidney disease. In older patients < 80 years of age with systolic blood pressure ≥ 160 mmHg, the systolic blood pressure should be lowered to 140–150 mmHg, with consideration of <140 mmHg. In patients >80 years of age with systolic blood pressure ≥ 160 mmHg, the systolic blood pressure should be lowered to 140–150 mmHg, provided they are in good physical and mental condition.PubMedCrossRef
5.••
go back to reference James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). 520. 2014;311:507. These guidelines recommend lowering systolic blood pressure to <150 mmHg in patients ≥ 60 years of age who do not have diabetes or chronic kidney disease and to <140 mmHg in patients with diabetes or chronic kidney disease. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). 520. 2014;311:507. These guidelines recommend lowering systolic blood pressure to <150 mmHg in patients ≥ 60 years of age who do not have diabetes or chronic kidney disease and to <140 mmHg in patients with diabetes or chronic kidney disease.
6.••
go back to reference Wright Jr JT, Fine LJ, Lackland DT, Ogedegbe G, Dennison-Himmelfarb C. Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older: the minority view. JAMA. 2014. doi:10.7326/M13–2981. The minority view from JNC 8 recommends a systolic blood pressure goal of < 140 mmHg in hypertensive patients <80 years of age without diabetes or chronic kidney disease. Wright Jr JT, Fine LJ, Lackland DT, Ogedegbe G, Dennison-Himmelfarb C. Evidence supporting a systolic blood pressure goal of less than 150 mmHg in patients aged 60 years or older: the minority view. JAMA. 2014. doi:10.​7326/​M13–2981. The minority view from JNC 8 recommends a systolic blood pressure goal of < 140 mmHg in hypertensive patients <80 years of age without diabetes or chronic kidney disease.
7.
go back to reference SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.CrossRef SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265:3255–64.CrossRef
8.
go back to reference Perry Jr HM, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465–71.PubMedCrossRef Perry Jr HM, Davis BR, Price TR, Applegate WB, Fields WS, Guralnik JM, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 2000;284:465–71.PubMedCrossRef
9.
go back to reference Kostis JB, Davis BR, Cutler J, Grimm Jr RH, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212–6.PubMedCrossRef Kostis JB, Davis BR, Cutler J, Grimm Jr RH, Berge KG, Cohen JD, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997;278:212–6.PubMedCrossRef
10.
go back to reference Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757–64.PubMedCrossRef Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350:757–64.PubMedCrossRef
11.
go back to reference Liu L, Wang JG, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16:1823–9.PubMedCrossRef Liu L, Wang JG, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens. 1998;16:1823–9.PubMedCrossRef
12.
go back to reference Staessen JA, Gasowski J, Wang JG, Thijs L, Den-Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–72.PubMedCrossRef Staessen JA, Gasowski J, Wang JG, Thijs L, Den-Hond E, Boissel JP, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865–72.PubMedCrossRef
13.
go back to reference Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRef Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358:1887–98.PubMedCrossRef
14.
go back to reference Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly systolic hypertension study. Hypertension. 2010;56:196–202.PubMedCrossRef Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly systolic hypertension study. Hypertension. 2010;56:196–202.PubMedCrossRef
15.
go back to reference Liu L, Zhang Y, Liu G, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157–72.PubMedCrossRef Liu L, Zhang Y, Liu G, Zhang X, Zanchetti A, FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. 2005;23:2157–72.PubMedCrossRef
16.
go back to reference Zhang Y, Zhang X, Liu L, Zanchetti A, FEVER Study Group. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32:1500–8.PubMedCrossRef Zhang Y, Zhang X, Liu L, Zanchetti A, FEVER Study Group. Is a systolic blood pressure target <140 mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. Eur Heart J. 2011;32:1500–8.PubMedCrossRef
17.
go back to reference Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo Jr JL, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88.PubMedCrossRef Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo Jr JL, et al. Treatment of hypertension in the prevention and management of ischemic heart disease. A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation. 2007;115:2761–88.PubMedCrossRef
19.
go back to reference Banach M, Michalska M, Kjeldsen SE, Malyszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12:1835–44.PubMedCrossRef Banach M, Michalska M, Kjeldsen SE, Malyszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12:1835–44.PubMedCrossRef
20.
go back to reference Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn. 2011;121:253–8.PubMed Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn. 2011;121:253–8.PubMed
21.
go back to reference Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press. 2012;21:3–5.PubMedCrossRef Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press. 2012;21:3–5.PubMedCrossRef
22.
go back to reference Banach M, Aronow WS. Hypertension therapy in the elderly-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Hum Hypertens. 2012;26:641–3.PubMedCrossRef Banach M, Aronow WS. Hypertension therapy in the elderly-do we know the answers to all the questions? The status after publication of the ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. J Hum Hypertens. 2012;26:641–3.PubMedCrossRef
24.
go back to reference Aronow WS. What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease. Arch Med Sci. 2012;8:399–402.PubMedCentralPubMedCrossRef Aronow WS. What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease. Arch Med Sci. 2012;8:399–402.PubMedCentralPubMedCrossRef
25.
go back to reference Aronow WS. Hypertension-related stroke prevention in the elderly. Curr Hypertens Rep. 2013;15:582–9.PubMedCrossRef Aronow WS. Hypertension-related stroke prevention in the elderly. Curr Hypertens Rep. 2013;15:582–9.PubMedCrossRef
26.
go back to reference Aronow WS, Banach M, Ahmed A. Hypertension and prevention of diastolic heart failure in the aging population. In: Jugdutt BI, editor. Aging and Heart Failure. Mechanisms and Management. New York City: Springer; 2014. p. 35–45.CrossRef Aronow WS, Banach M, Ahmed A. Hypertension and prevention of diastolic heart failure in the aging population. In: Jugdutt BI, editor. Aging and Heart Failure. Mechanisms and Management. New York City: Springer; 2014. p. 35–45.CrossRef
27.
go back to reference Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, PROVE. IT-TIMI Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142–51.PubMedCrossRef Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP, PROVE. IT-TIMI Investigators. What is the optimal blood pressure in patients after acute coronary syndromes? Relationship of blood pressure and cardiovascular events in the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142–51.PubMedCrossRef
28.
go back to reference Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8.PubMedCentralPubMedCrossRef Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61–8.PubMedCentralPubMedCrossRef
29.
go back to reference The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.PubMedCentralCrossRef The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.PubMedCentralCrossRef
30.
go back to reference Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727–36.PubMedCrossRef Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124:1727–36.PubMedCrossRef
31.
go back to reference Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541–8.PubMedCrossRef Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541–8.PubMedCrossRef
32.
go back to reference Appel LJ, Wright Jr JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–29.PubMedCentralPubMedCrossRef Appel LJ, Wright Jr JT, Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010;363:918–29.PubMedCentralPubMedCrossRef
33.
go back to reference Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641–50.PubMedCrossRef Lazarus JM, Bourgoignie JJ, Buckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low blood pressure goal in chronic renal disease: the Modification of Diet in Renal Disease Study Group. Hypertension. 1997;29:641–50.PubMedCrossRef
34.
go back to reference Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-lordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939–46.PubMedCrossRef Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-lordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with nondiabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939–46.PubMedCrossRef
35.
go back to reference Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208–14.PubMedCentralPubMedCrossRef Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, et al. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208–14.PubMedCentralPubMedCrossRef
36.
go back to reference Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011;306:2137–44.PubMedCrossRef Ovbiagele B, Diener HC, Yusuf S, Martin RH, Cotton D, Vinisko R, et al. Level of systolic blood pressure within the normal range and risk of recurrent stroke. JAMA. 2011;306:2137–44.PubMedCrossRef
37.
go back to reference The SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:515–07. The SPS3 Study Group. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:515–07.
38.
go back to reference Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS et al. Optimal blood pressure levels in elderly persons in the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study. Presented at 2013 European Society of Cardiology (ESC) Meeting, Hot Line-Clinical Trial Update Sessions, Amsterdam, the Netherlands. Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS et al. Optimal blood pressure levels in elderly persons in the REasons for Geographic and Racial Differences in Stroke (REGARDS) cohort study. Presented at 2013 European Society of Cardiology (ESC) Meeting, Hot Line-Clinical Trial Update Sessions, Amsterdam, the Netherlands.
40.
go back to reference Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS et al. What are the blood pressure levels associated with the lowest stroke rates in the elderly? Findings from the Reasons for Geographic and Racial differences in stroke (REGARDS) cohort study. Stroke 2014; 44 (Suppl): ATPM99. Banach M, Bromfield S, Howard G, Howard VJ, Zanchetti A, Aronow WS et al. What are the blood pressure levels associated with the lowest stroke rates in the elderly? Findings from the Reasons for Geographic and Racial differences in stroke (REGARDS) cohort study. Stroke 2014; 44 (Suppl): ATPM99.
41.
go back to reference Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet. 2003;362:591–2.PubMedCrossRef Aronow WS. Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet. 2003;362:591–2.PubMedCrossRef
42.
go back to reference Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684–9.PubMedCrossRef Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684–9.PubMedCrossRef
43.
go back to reference Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother. 2010;11:2599–607.PubMedCrossRef Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother. 2010;11:2599–607.PubMedCrossRef
44.••
go back to reference American Diabetes Association. Position statement. Standards of Medical Care in Diabetes-2013. Diabetes Care. 2013;36(1):S11–66. The American Diabetes Society 2013 guidelines recommend a systolic blood pressure goal of < 140 mmHg for diabetics.PubMedCentralCrossRef American Diabetes Association. Position statement. Standards of Medical Care in Diabetes-2013. Diabetes Care. 2013;36(1):S11–66. The American Diabetes Society 2013 guidelines recommend a systolic blood pressure goal of < 140 mmHg for diabetics.PubMedCentralCrossRef
45.••
go back to reference KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 3. Blood pressure management in CKD ND patients without diabetes mellitus. Kidney Int Supplements 2012; 2:357–362. These guidelines recommend a systolic blood pressure goal of ≤140 mmHg in patients with non-dialysis-dependent chronic kidney disease with hypertension and albuminuria <30 mg/24 hours. If albuminuria >30 mg/24 hours is present, the systolic blood pressure may be lowered to ≤130 mmHg with a class II D indication. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 3. Blood pressure management in CKD ND patients without diabetes mellitus. Kidney Int Supplements 2012; 2:357–362. These guidelines recommend a systolic blood pressure goal of ≤140 mmHg in patients with non-dialysis-dependent chronic kidney disease with hypertension and albuminuria <30 mg/24 hours. If albuminuria >30 mg/24 hours is present, the systolic blood pressure may be lowered to ≤130 mmHg with a class II D indication.
46.••
go back to reference KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 4. Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Supplements 2012; 2:363–369. These guidelines recommend a systolic blood pressure goal of ≤140 mmHg in patients with non-dialysis-dependent chronic kidney disease with hypertension and albuminuria <30 mg/24 hours. If albuminuria >30 mg/24 hours is present, systolic blood pressure may be lowered to ≤130 mmHg with a class II D indication. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Chapter 4. Blood pressure management in CKD ND patients with diabetes mellitus. Kidney Int Supplements 2012; 2:363–369. These guidelines recommend a systolic blood pressure goal of ≤140 mmHg in patients with non-dialysis-dependent chronic kidney disease with hypertension and albuminuria <30 mg/24 hours. If albuminuria >30 mg/24 hours is present, systolic blood pressure may be lowered to ≤130 mmHg with a class II D indication.
Metadata
Title
What Should the Systolic Blood Pressure Treatment Goal Be in Patients Aged 60 Years and Older with Hypertension?
Author
Wilbert S. Aronow
Publication date
01-12-2014
Publisher
Springer US
Published in
Current Geriatrics Reports / Issue 4/2014
Electronic ISSN: 2196-7865
DOI
https://doi.org/10.1007/s13670-014-0086-5

Other articles of this Issue 4/2014

Current Geriatrics Reports 4/2014 Go to the issue

Geriatric Psychiatry (GT Grossberg, Section Editor)

Management of Behavioral and Psychological Symptoms of Dementia

Geriatric Psychiatry (GT Grossberg, Section Editor)

Recent Advances in Delirium Recognition and Management

Geriatric Psychiatry (GT Grossberg, Section Editor)

Anxiety Disorders in Older Adults

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.